Donald M Arnold1,2, Ishac Nazi1, Lisa J Toltl1, Catherine Ross3, Nikola Ivetic4, James W Smith1, Yang Liu1, John G Kelton1. 1. Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. 2. Canadian Blood Services, Hamilton, Ontario, Canada. 3. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. 4. Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Abstract
OBJECTIVES: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder caused by increased platelet destruction and impaired platelet production. Antibody binding to megakaryocytes may occur in ITP, but in vivo evidence of this phenomenon is lacking. METHODS: We determined the proportion of megakaryocytes bound with immunoglobulin G (IgG) in bone marrow samples from primary patients with ITP (n = 17), normal controls (n = 13) and thrombocytopenic patients with myelodysplastic syndrome (MDS; n = 10). Serial histological sections from archived bone marrow biopsies were stained for CD61 and IgG. IgG binding and the number of bone marrow megakaryocytes were determined morphologically by a hematopathologist with four assessors after a calibration exercise to ensure consistency. RESULTS: The proportion of ITP patients with high IgG binding (>50% of bone marrow megakaryocytes) was increased compared with normal controls [12/17 (71%) vs. 3/13 (23%), P = 0.03]. However, the proportion of ITP patients with high IgG binding was no different than thrombocytopenic patients with MDS [12/17 (71%) vs. 7/10 (70%), P = 1.00]. IgG binding was associated with increased megakaryocyte numbers. Like platelet-associated IgG, megakaryocyte-associated IgG is related to thrombocytopenia but may not be specific for ITP. CONCLUSION: Mechanistic studies in ITP should focus on antibody specificity and include thrombocytopenic control patients.
OBJECTIVES: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder caused by increased platelet destruction and impaired platelet production. Antibody binding to megakaryocytes may occur in ITP, but in vivo evidence of this phenomenon is lacking. METHODS: We determined the proportion of megakaryocytes bound with immunoglobulin G (IgG) in bone marrow samples from primary patients with ITP (n = 17), normal controls (n = 13) and thrombocytopenicpatients with myelodysplastic syndrome (MDS; n = 10). Serial histological sections from archived bone marrow biopsies were stained for CD61 and IgG. IgG binding and the number of bone marrow megakaryocytes were determined morphologically by a hematopathologist with four assessors after a calibration exercise to ensure consistency. RESULTS: The proportion of ITP patients with high IgG binding (>50% of bone marrow megakaryocytes) was increased compared with normal controls [12/17 (71%) vs. 3/13 (23%), P = 0.03]. However, the proportion of ITP patients with high IgG binding was no different than thrombocytopenicpatients with MDS [12/17 (71%) vs. 7/10 (70%), P = 1.00]. IgG binding was associated with increased megakaryocyte numbers. Like platelet-associated IgG, megakaryocyte-associated IgG is related to thrombocytopenia but may not be specific for ITP. CONCLUSION: Mechanistic studies in ITP should focus on antibody specificity and include thrombocytopenic control patients.
Authors: David J Kuter; James B Bussel; Adrian Newland; Ross I Baker; Roger M Lyons; Jeffrey Wasser; Jean-Francois Viallard; Gail Macik; Mathias Rummel; Kun Nie; Susie Jun Journal: Br J Haematol Date: 2013-02-22 Impact factor: 6.998
Authors: Vishwanath K Mahabir; Catherine Ross; Snezana Popovic; Mona Lisa Sur; Jacqueline Bourgeois; Wendy Lim; James N George; Grace Wang; Richard J Cook; Lisa J Toltl; Ishac Nazi; John G Kelton; Donald M Arnold Journal: Eur J Haematol Date: 2012-12-13 Impact factor: 2.997
Authors: Mei Chang; Peggy A Nakagawa; Shirley A Williams; Michael R Schwartz; Karen L Imfeld; Jeffrey S Buzby; Diane J Nugent Journal: Blood Date: 2003-04-03 Impact factor: 22.113
Authors: Mansoor N Saleh; James B Bussel; Gregory Cheng; Oliver Meyer; Christine K Bailey; Michael Arning; Andres Brainsky Journal: Blood Date: 2012-11-20 Impact factor: 22.113
Authors: Paola R Lev; Matías Grodzielski; Nora P Goette; Ana C Glembotsky; Yesica R Espasandin; Marta S Pierdominici; Geraldine Contrufo; Verónica S Montero; Luciana Ferrari; Felisa C Molinas; Paula G Heller; Rosana F Marta Journal: Br J Haematol Date: 2014-03-27 Impact factor: 6.998
Authors: Doaa I Elzaeem; Esmat A El Sharkawi; Eman M Zaki; Ayman G Ghobrial; Aliaa S Abd El-Fatah; Waleed M Abd El-Hamed Journal: Ann Hematol Date: 2021-05-13 Impact factor: 3.673
Authors: Tadeusz Robak; Maciej Kaźmierczak; Isidro Jarque; Vasile Musteata; Jacek Treliński; Nichola Cooper; Peter Kiessling; Ute Massow; Franz Woltering; Rose Snipes; Juan Ke; Grant Langdon; James B Bussel; Stephen Jolles Journal: Blood Adv Date: 2020-09-08
Authors: Young Eun Park; Rushi Penumarthy; Paul P Sun; Caroline Y Kang; Marie-Christine Morel-Kopp; Jonathan Downing; Taryn N Green; Tracey Immanuel; Christopher M Ward; Deborah Young; Matthew J During; P Alan Barber; Maggie L Kalev-Zylinska Journal: Int J Mol Sci Date: 2020-11-09 Impact factor: 5.923